Pharmagreen Biotech (Pharmagreen Biotech) Cash-to-Debt : 0.01 (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pharmagreen Biotech's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Pharmagreen Biotech couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Pharmagreen Biotech's Cash-to-Debt or its related term are showing as below:

PHBI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.07 Max: 152
Current: 0.01

During the past 7 years, Pharmagreen Biotech's highest Cash to Debt Ratio was 152.00. The lowest was 0.01. And the median was 0.07.

PHBI's Cash-to-Debt is ranked worse than
97.33% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs PHBI: 0.01

Pharmagreen Biotech Cash-to-Debt Historical Data

The historical data trend for Pharmagreen Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pharmagreen Biotech Cash-to-Debt Chart

Pharmagreen Biotech Annual Data

Trend

Apr08

Apr09

Sep18

Sep19

Sep20

Sep21

Sep22

Cash-to-Debt

Get a 7-Day Free Trial

152.00

0.82

0.02

0.09

0.02

Pharmagreen Biotech Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial															0.06	0.02	0.06	0.02	0.01

Competitive Comparison of Pharmagreen Biotech's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's Cash-to-Debt falls into.

Pharmagreen Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pharmagreen Biotech's Cash to Debt Ratio for the fiscal year that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.008	/	(0.219	+	0.119)
	=	0.02

Pharmagreen Biotech's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.005	/	(0.28	+	0.12)
	=	0.01

Pharmagreen Biotech (OTCPK:PHBI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pharmagreen Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

112 North Curry Street, Carson, NV, USA, 89703

Website

https://www.pharmagreen.ca

Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.